company background image
BLPH logo

Bellerophon Therapeutics OTCPK:BLPH Stock Report

Last Price

US$0.057

Market Cap

US$695.0k

7D

11.2%

1Y

-99.3%

Updated

27 Mar, 2024

Data

Company Financials

Bellerophon Therapeutics, Inc.

OTCPK:BLPH Stock Report

Market Cap: US$695.0k

BLPH Stock Overview

Bellerophon Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States.

BLPH fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health4/6
Dividends0/6

Bellerophon Therapeutics, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Bellerophon Therapeutics
Historical stock prices
Current Share PriceUS$0.057
52 Week HighUS$12.58
52 Week LowUS$0.029
Beta0.66
1 Month Change6.69%
3 Month Change67.10%
1 Year Change-99.26%
3 Year Change-98.91%
5 Year Change-99.43%
Change since IPO-99.96%

Recent News & Updates

Recent updates

Bellerophon Therapeutics (NASDAQ:BLPH) Will Have To Spend Its Cash Wisely

Jan 06
Bellerophon Therapeutics (NASDAQ:BLPH) Will Have To Spend Its Cash Wisely

Bellerophon stock gains ~24% after getting FDA nod to reduce phase 3 study size

Sep 27

Bellerophon Therapeutics GAAP EPS of -$0.43 beats by $0.17

Aug 15

Is Bellerophon Therapeutics (NASDAQ:BLPH) In A Good Position To Invest In Growth?

Jan 18
Is Bellerophon Therapeutics (NASDAQ:BLPH) In A Good Position To Invest In Growth?

Bellerophon Therapeutics EPS misses by $0.01

Nov 05

Shareholder Returns

BLPHUS BiotechsUS Market
7D11.2%0.9%0.4%
1Y-99.3%10.3%28.8%

Return vs Industry: BLPH underperformed the US Biotechs industry which returned 9.6% over the past year.

Return vs Market: BLPH underperformed the US Market which returned 29.5% over the past year.

Price Volatility

Is BLPH's price volatile compared to industry and market?
BLPH volatility
BLPH Average Weekly Movement17.6%
Biotechs Industry Average Movement11.6%
Market Average Movement6.0%
10% most volatile stocks in US Market16.9%
10% least volatile stocks in US Market3.0%

Stable Share Price: BLPH's share price has been volatile over the past 3 months.

Volatility Over Time: BLPH's weekly volatility has decreased from 23% to 18% over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
200918Craig Jalberthttps://bellerophon.com

Bellerophon Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its primary product is INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension. The company engages in the development of INOpulse, which is in Phase 3 clinical trial for the treatment of pulmonary hypertension associated with fibrotic interstitial lung disease; which has completed Phase 2a clinical trial for pulmonary hypertension associated with chronic obstructive pulmonary disease; and that has completed Phase 2 dose escalation stage for pulmonary hypertension associated with sarcoidosis, as well as for chronic thromboembolic pulmonary hypertension and pulmonary hypertension associated with pulmonary edema from high altitude sickness.

Bellerophon Therapeutics, Inc. Fundamentals Summary

How do Bellerophon Therapeutics's earnings and revenue compare to its market cap?
BLPH fundamental statistics
Market capUS$695.00k
Earnings (TTM)-US$9.25m
Revenue (TTM)US$5.64m

0.1x

P/S Ratio

-0.1x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
BLPH income statement (TTM)
RevenueUS$5.64m
Cost of RevenueUS$0
Gross ProfitUS$5.64m
Other ExpensesUS$14.89m
Earnings-US$9.25m

Last Reported Earnings

Sep 30, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-0.76
Gross Margin100.00%
Net Profit Margin-164.06%
Debt/Equity Ratio0%

How did BLPH perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.